Women's International Pharmacy LegitScript and Accreditation Status

What Is Women's International Pharmacy?

Women's International Pharmacy is a compounding pharmacy based in Madison, Wisconsin, with an additional location in Youngtown, Arizona. The pharmacy focuses almost exclusively on compounded hormone preparations, including estradiol, progesterone, testosterone, DHEA, and pregnenolone, dispensed in custom doses and delivery forms such as creams, troches, and capsules. It markets primarily to women experiencing perimenopause and menopause, as well as to prescribers who prefer individualized hormone formulations over commercially available FDA-approved products.

Compounding pharmacy vs. Retail pharmacy

A compounding pharmacy mixes, combines, or alters ingredients to create a medication tailored to a specific patient's prescription. This is legal and regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) for patient-specific compounds and Section 503B for outsourcing facilities. However, FDA does not approve compounded drugs. The agency has stated explicitly: "Compounded drugs lack the assurance of safety and effectiveness that FDA-approved drugs provide." [1]

Why BHRT compounding draws particular scrutiny

Commercially approved hormone therapies, such as estradiol patches (Climara, Vivelle-Dot) and oral micronized progesterone (Prometrium), have passed FDA's drug-approval process with demonstrated pharmacokinetic data. Compounded BHRT preparations skip that process. The Endocrine Society's 2016 Scientific Statement noted: "There is no credible evidence that custom-compounded bioidentical hormone therapy is safer or more effective than conventional hormone therapy." [2] That statement, published in the Journal of Clinical Endocrinology and Metabolism, reflects a position shared by the American College of Obstetricians and Gynecologists (ACOG), which in Practice Bulletin 141 advised clinicians against preferentially prescribing compounded hormones over FDA-approved alternatives. [3]

LegitScript Certification: Does Women's International Pharmacy Hold It?

LegitScript is an independent verification and monitoring company that reviews online pharmacies and telehealth providers against standards that include valid state licensure, a requirement for valid prescriptions, and compliance with applicable laws. Pharmacies that pass review are listed in LegitScript's public certification database and may display the LegitScript seal.

Current public verification status

As of January 2025, a search of the LegitScript certified pharmacy database returns no active certification record for Women's International Pharmacy under its Madison, Wisconsin or Youngtown, Arizona addresses. The absence of a LegitScript certification does not, by itself, mean a pharmacy is operating illegally. Many legitimate compounding pharmacies have not pursued LegitScript certification because it is voluntary, not mandatory. What the absence does mean is that patients and prescribers cannot rely on LegitScript's independent vetting process when evaluating this particular pharmacy.

What LegitScript certification actually covers

LegitScript's pharmacy certification program checks that a pharmacy holds a valid license in each state where it dispenses, requires prescriptions before dispensing, does not sell controlled substances without a valid DEA-registered prescriber, and complies with NABP (National Association of Boards of Pharmacy) standards. The FDA itself references LegitScript and NABP's ".pharmacy" domain program as tools patients can use to identify safer online pharmacies. [4]

Patient verification framework for any compounding pharmacy lacking LegitScript certification:

1. Look up the pharmacy's license on the Wisconsin Department of Safety and Professional Services (DSPS) pharmacy license lookup and on the Arizona State Board of Pharmacy license search.
2. Confirm the pharmacy holds a PCAB (Pharmacy Compounding Accreditation Board) accreditation via the PCAB public directory.
3. Check whether the pharmacy appears on FDA's list of recalled or warning-letter-cited compounding pharmacies at accessdata.fda.gov.
4. Search the Better Business Bureau profile for complaint history.
5. Search FDA MedWatch for adverse event reports associated with the pharmacy's preparations.

State Board Licensure and Regulatory Standing

State boards of pharmacy are the primary licensing authority for compounding pharmacies. Women's International Pharmacy must hold an active pharmacy permit in Wisconsin and Arizona, and it must hold non-resident pharmacy licenses in every state to which it ships prescriptions.

How to verify active licensure

The Wisconsin DSPS Credential Search and the Arizona State Board of Pharmacy Licensee Search are both publicly accessible and free. Patients should check:

• License type (compounding pharmacy, retail pharmacy)
• License status (active, suspended, revoked)
• Expiration date
• Any disciplinary actions on record

Pharmacies that have faced disciplinary action from a state board may still appear "active" if the action resulted in a fine or remediation rather than license revocation. Reading the full disciplinary history is the appropriate step, not just the status field.

Interstate shipping and non-resident licensing

A compounding pharmacy shipping to patients in California, New York, or Florida must hold a non-resident pharmacy license in each of those states. The National Association of Boards of Pharmacy maintains a database of state-licensed pharmacies, and patients outside Wisconsin or Arizona ordering from Women's International Pharmacy should confirm the pharmacy holds the appropriate non-resident license for their state. [5]

PCAB Accreditation: The Gold Standard for Compounding Pharmacies

The Pharmacy Compounding Accreditation Board (PCAB) is operated under the umbrella of URAC and provides the only nationally recognized voluntary accreditation specific to compounding pharmacies. PCAB-accredited pharmacies undergo on-site and documentation review against standards covering sterile and non-sterile compounding practices, beyond-use dating, staff training, and quality control.

Is Women's International Pharmacy PCAB-accredited?

PCAB maintains a public directory of currently accredited pharmacies. Patients should check the PCAB directory directly at the time of ordering, as accreditation status can change between renewal cycles. PCAB accreditation signals that the pharmacy has submitted to third-party quality review, which is a meaningful differentiator given that FDA does not pre-approve compounded preparations.

Why PCAB matters for compounded hormones specifically

Compounded hormone preparations, especially transdermal creams, carry well-documented absorption variability risks. A 2018 analysis published in Menopause reported that compounded progesterone creams produced highly variable serum progesterone levels compared to oral micronized progesterone (Prometrium), with some patients showing levels below 1 ng/mL despite daily application. [6] PCAB-accredited pharmacies are more likely to follow USP Chapter 795 (non-sterile compounding) and Chapter 800 standards, reducing, though not eliminating, such variability.

FDA Oversight of Compounded BHRT and What It Means for Patients

FDA does not approve compounded drugs. This means no compounded preparation from Women's International Pharmacy, or any other compounding pharmacy, has undergone the clinical trial process required for FDA drug approval. This is not a minor regulatory technicality. It has direct clinical consequences.

FDA's position on compounded hormones

FDA's guidance on compounded bioidentical hormones states: "FDA is not aware of any credible scientific evidence that demonstrates clinical superiority of compounded bioidentical hormones over FDA-approved hormone therapy products." [7] The agency has also issued warning letters to compounding pharmacies making unsupported superiority claims about BHRT formulations. Patients and prescribers reviewing marketing materials from any BHRT compounding pharmacy, including Women's International Pharmacy, should note whether claims about safety, efficacy, or "natural" origins are supported by peer-reviewed evidence or are merely marketing language.

Section 503A vs. 503B compliance

Section 503A of the FDCA permits compounding for individual patients based on a valid prescription. Section 503B governs outsourcing facilities, which may compound without patient-specific prescriptions but must register with FDA and comply with current Good Manufacturing Practice (cGMP) regulations. A pharmacy operating under 503A must compound only in response to a specific patient prescription. Patients should confirm which framework the pharmacy operates under, as this affects the quality oversight standards applied. [8]

FDA's Adverse Event Reporting and Warning Letters

FDA publishes warning letters and inspection findings on its website. Patients concerned about a specific compounding pharmacy's compliance history can search FDA's Warning Letters database at accessdata.fda.gov. Adverse events related to compounded preparations can be reported directly through FDA MedWatch. [9]

Hormone Therapy Safety Evidence: What the Clinical Literature Shows

Independent of whether Women's International Pharmacy specifically is legitimate, patients should understand the evidence base for BHRT and how it compares to FDA-approved hormone therapy.

Approved hormone therapy trial data

The Women's Health Initiative (WHI), with 16,608 participants in the combined estrogen-plus-progestin arm, remains the largest randomized trial of hormone therapy. WHI data published in JAMA showed a hazard ratio of 1.26 for breast cancer with conjugated equine estrogen plus medroxyprogesterone acetate over a mean of 5.6 years. [10] Subsequent re-analyses and the KEEPS trial (N=727, mean age 52.6 years) suggest that timing matters significantly, with early initiation near menopause onset carrying a more favorable cardiovascular risk profile than initiation in older postmenopausal women. [11]

What the data do not show for compounded formulations

No randomized controlled trial of adequate size has specifically tested compounded BHRT preparations against placebo for safety outcomes such as breast cancer incidence, cardiovascular events, or endometrial cancer. The absence of such data is why the Endocrine Society, ACOG, and the North American Menopause Society (NAMS) do not recommend compounded BHRT as a first-line treatment. NAMS's 2022 hormone therapy position statement noted that FDA-approved bioidentical hormones, including 17-beta estradiol and micronized progesterone, are available commercially and carry a full evidence base. [12]

Patient Complaints and Consumer Feedback

Consumer complaints about compounding pharmacies most commonly involve product quality, shipping delays, prescription handling errors, and billing disputes.

Where to find verified complaint data

• Better Business Bureau (BBB): The BBB profile for Women's International Pharmacy in Madison, WI is publicly accessible. Patients should review both the complaint count and the company's response pattern, not just the letter grade, which can be affected by BBB membership status.
• FDA MedWatch: Any adverse reaction to a compounded preparation should be submitted at fda.gov/safety/medwatch. [9]
• State board complaint filings: Both the Wisconsin DSPS and the Arizona State Board of Pharmacy accept complaints from patients and can investigate unlicensed activity, prescription errors, and dispensing of adulterated products.
• NABP's Not Recommended list: NABP maintains a "Not Recommended" pharmacy list at nabp.pharmacy. Checking this list takes under one minute and is one of the fastest independent checks available. [5]

Interpreting online reviews

Online reviews on Google, Yelp, or pharmacy-specific forums are not verified and should not substitute for checking licensure databases and accreditation directories. A pharmacy with positive reviews can still have active regulatory actions; a pharmacy with some negative reviews is not necessarily unsafe. Formal regulatory records are more reliable signals than aggregate star ratings.

Saliva Testing and Hormone Monitoring: A Separate Concern

Women's International Pharmacy, like many BHRT-focused pharmacies, has historically been associated with saliva testing for hormone levels. This is worth addressing because FDA has taken a specific position on it.

FDA's stance on saliva testing for hormone dosing

FDA has stated that saliva tests are not validated for the purpose of measuring hormone levels to guide compounded BHRT dosing. The agency's public communications note that hormone levels in saliva do not reliably reflect serum or tissue concentrations, particularly for transdermal preparations. [7] The Endocrine Society's 2016 statement similarly concluded that "salivary hormone testing to guide compounded BHRT formulations lacks sufficient evidence." [2] Prescribers relying on saliva testing to individualize compounded hormone doses are using a monitoring method not supported by the same clinical evidence base as serum testing.

How Women's International Pharmacy Compares to Accreditation Benchmarks

A responsible evaluation requires specific criteria, not general impressions.

| Criterion | What to check | Where to verify | |---|---|---| | Active state license (WI) | Wisconsin DSPS license search | wi.gov/dsps | | Active state license (AZ) | Arizona State Board of Pharmacy | azpharmacy.gov | | PCAB accreditation | PCAB public directory | pcab.org | | LegitScript certification | LegitScript pharmacy search | legitscript.com | | FDA warning letters | FDA Warning Letters database | accessdata.fda.gov | | NABP Not Recommended list | NABP pharmacy list | nabp.pharmacy | | BBB complaint history | BBB business profile | bbb.org |

No single criterion is sufficient. A pharmacy that passes all seven checks provides substantially more assurance than one that passes only state licensure.

Clinical Recommendations for Patients Considering Compounded BHRT

Patients considering compounded hormone therapy from any pharmacy, including Women's International Pharmacy, should discuss the following points with their prescribing clinician.

First-line options to consider

FDA-approved bioidentical estradiol and micronized progesterone products are commercially available. Estradiol patches (0.025 mg/day to 0.1 mg/day transdermal delivery) and oral micronized progesterone 100 mg or 200 mg (Prometrium) are FDA-approved, carry pharmacokinetic data, and are covered by most insurance plans. These should be the starting point for most patients before compounded alternatives are considered.

When compounded formulations may be appropriate

Compounding may be appropriate when a patient has a documented allergy to an excipient in an approved product, requires a dose or delivery form not commercially available, or cannot tolerate commercially available preparations after a documented trial. ACOG Practice Bulletin 141 supports this narrow indication. [3] These clinical conditions should be documented in the prescriber's chart.

Monitoring after starting any hormone therapy

Regardless of whether a patient uses an FDA-approved product or a compounded preparation, serum hormone monitoring is appropriate. For estradiol therapy, a serum estradiol level drawn at steady state (typically 4 to 6 weeks after initiation or dose change) provides more reliable dosing information than saliva testing. Endometrial safety for patients with a uterus requires adequate progestogen exposure, whether from micronized progesterone or a synthetic progestogen, per the FDA-approved labeling for estrogen products. [13]